Syndax Pharmaceuticals (SNDX) Change in Receivables (2022 - 2026)

Syndax Pharmaceuticals' Change in Receivables history runs 5 years deep, the most recent figure standing at -$120000.0 for Q1 2026.

• In Q1 2026, Change in Receivables fell 101.48% year-over-year to -$120000.0; the TTM figure through Mar 2026 stood at -$1.8 million (down 118.7% YoY), while the FY2025 annual figure was $6.4 million, down 15.34% from the prior year.
• Change in Receivables for Q1 2026 stood at -$120000.0, up from -$11.4 million in the prior quarter.
• The five-year high for Change in Receivables was $8.6 million in Q3 2022, with the low at -$11.4 million in Q4 2025.
• The 5-year median for Change in Receivables is $3.5 million (2024), against an average of $1.8 million.
• Peak annual rise in Change in Receivables reached 6122.06% in 2024, while the deepest fall reached 9033.82% in 2024.
• Syndax Pharmaceuticals' Change in Receivables stood at $4.5 million in 2022, then plunged by 101.5% to -$68000.0 in 2023, then soared by 6122.06% to $4.1 million in 2024, then sank by 377.53% to -$11.4 million in 2025, then soared by 98.94% to -$120000.0 in 2026.
• Business Quant data shows SNDX's Change in Receivables at -$120000.0 in Q1 2026, -$11.4 million in Q4 2025, and $5.9 million in Q3 2025.